News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

October 7, 2020

BioWorld

Read Now

Press Release

Starting with Biogen deal in ALS, Scribe planning a new chapter in CRISPR story

October 7, 2020

BioWorld

Read Now

Press Release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now

Press Release

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases Including ALS

October 6, 2020

Read Now

Press Release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

Press Release

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

October 6, 2020

Read Now

News

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

October 6, 2020

Reuters

Read Now

Press Release

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

October 6, 2020

Reuters

Read Now

News

Scribe Therapeutics launches to explore next-generation CRISPR technology

October 6, 2020

Chemical & Engineering News

Read Now

Press Release

Scribe Therapeutics launches to explore next-generation CRISPR technology

October 6, 2020

Chemical & Engineering News

Read Now

News

CRISPR startup Scribe Therapeutics lands big Biogen deal

October 6, 2020

San Francisco Business Times

Read Now

Press Release

CRISPR startup Scribe Therapeutics lands big Biogen deal

October 6, 2020

San Francisco Business Times

Read Now

News

From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need

December 6, 2024

Forbes Healthcare Summit

Read Now

News

Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies

November 27, 2024

Inside Precision Medicine

Read Now

News

The 2024 PharmaVoice 100

October 8, 2024

PharmaVoice

Read Now

News

Engineering The Future Of Genetic Medicine

September 10, 2024

Progress, Potential, and Possibilities

Read Now

News

Leadership essentials: “Inspire, motivate, and cultivate”

September 9, 2024

BigThink

Read Now

News

Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

August 5, 2024

BioSpace

Read Now

Press release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now

Press release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now

Press release

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

September 27, 2022

Read Now

Press release

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now

Press release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

Publications and presentations

Presentation

Scribe Corporate Deck 2025 Q1

February 3, 2025

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now